Ampio Pharmaceuticals, Inc. (AMPE) SEC Filing 10-Q Quarterly report for the period ending Friday, March 31, 2017

Ampio Pharmaceuticals, Inc.

CIK: 1411906 Ticker: AMPE
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2017
May 01, 2017
Document Information [Line Items]  
Document Type10-Q 
Amendment Flagfalse 
Document Period End DateMar. 31, 2017 
Document Fiscal Year Focus2017 
Document Fiscal Period FocusQ1 
Entity Registrant NameAmpio Pharmaceuticals, Inc. 
Entity Central Index Key0001411906 
Current Fiscal Year End Date--12-31 
Entity Filer CategoryAccelerated Filer 
Trading SymbolAMPE 
Entity Common Stock, Shares Outstanding 57,242,164

View differences made from one quarter to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Ampio Pharmaceuticals, Inc..


Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Balance Sheets
Balance Sheets (parenthetical)
Statements Of Cash Flows
Statements Of Operations
Statements Of Stockholders’ Equity
Basis Of Presentation
Basis Of Presentation (policies)
Basis Of Presentation - Additional Information (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Rent Expense (detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (detail)
Common Stock
Common Stock (tables)
Common Stock - Additional Information (detail)
Common Stock - Sales (detail)
Equity Instruments
Equity Instruments (tables)
Equity Instruments - Additional Information (detail)
Equity Instruments - Assumptions Used In Computing Fair Value Of All Options Granted (detail)
Equity Instruments - Stock Option Activity (detail)
Equity Instruments - Summary Of Stock Options Outstanding And Exercisable (detail)
Equity Instruments - Summary Of Stock-based Compensation Expense (detail)
Equity Instruments - Warrants Issued In Conjunction With Its Senior Convertible Debentures (detail)
Fair Value Considerations
Fair Value Considerations (tables)
Fair Value Considerations - Additional Information (detail)
Fair Value Considerations - Aytu’s Closing Stock Price (detail)
Fair Value Considerations - Financial Assets And Liabilities (detail)
Fair Value Considerations - Sets Forth A Reconciliation Of Changes (detail)
Fixed Assets
Fixed Assets (details)
Fixed Assets (tables)
Going Concern
Going Concern (details Textual)
Litigation - Additional Information (detail)
Related Party Transactions
Related Party Transactions - Additional Information (detail)
Trading Security Aytu Bioscience, Inc.
Trading Security Aytu Bioscience, Inc.- Additional Information (detail)

Material Contracts, Statements, Certifications & more

Ampio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AMPE
CIK: 1411906
Form Type: 10-Q Quarterly Report
Accession Number: 0001144204-17-026953
Submitted to the SEC: Fri May 12 2017 5:20:16 PM EST
Accepted by the SEC: Fri May 12 2017
Period: Friday, March 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: